The Health Sciences Institute is intended to provide cutting-edge health information.
Nothing on this site should be interpreted as personal medical advice. Always consult with your doctor before changing anything related to your healthcare.

Vioxx -- FUBAR

Beyond All Recognition

Remember phone booths? Back in the 1940s, phone booth repairmen began using two acronyms: SNAFU and FUBAR.

SNAFU stands for “Situation normal, all fouled up.” And FUBAR: “Fouled up beyond all recognition.” (When these acronyms became part of military jargon they were given a profane twist, which you might be familiar with.)

For giant drug company Merck and the New England Journal of Medicine, the Vioxx fiasco has now made the full journey from SNAFU to FUBAR. Along the way, we’ve been given a glimpse of the astounding greed and deception that goes on when a drug company puts a priority on marketing at the expense of consumer safety.

How low can you go?

For those who may be new to the Vioxx mess, here’s a quick recap:

  • We first warned HSI members about the risks of Vioxx in a 2002 e-Alert
  • In 2004, Merck took Vioxx off the market after a study revealed cardiovascular risks associated with the drug
  • According to a Senate investigation, FDA officials tried to suppress a report prepared by the agency that concluded “27,000 heart attacks and sudden cardiac deaths” could have been avoided if patients had been using Celebrex instead of Vioxx

The first of possibly thousands of lawsuits filed against Merck began in 2005. So far, Merck has won three and lost three. But now those three losses are in serious jeopardy of being overturned.

One of the few strong points in the Merck defense has been a statement that appeared in NEJM supporting data suggesting the drug’s risks became a problem only after 18 months of use.

But many experts disputed that claim. In the e-Alert “What Would Judy Say?” (12/19/05), I told you about trial testimony by Eric Topol, M.D., chairman of the cardiovascular medicine department at the Cleveland Clinic. The trial concerned a man who had a fatal heart attack after only one month of Vioxx use. Dr. Topol cited research that revealed Vioxx might prompt heart attacks at any time after use begins.

From concern to correction

The worm began to turn in December 2005 when NEJM editors issued an “expression of concern” stating that damaging clinical evidence had been suppressed.

Last week, NEJM editors issued a correction that will appear in the July 13 issue.

NEJM executive editor Dr. Gregory D. Curfman told the Boston Globe that the correction is intended to make clear that any suggestion that heart attack risk only occurs after 18 months of Vioxx use is “a misinterpretation of the data.”

Oh stop being so polite! Just come out and say it! Merck deliberately concealed important data that makes the 18-month claim a lie! Dr. Curfman was more on point last December when he gave this statement to HealthDay: “We have very solid evidence that important data on cardiac events was deleted or withheld, which rendered the study of suboptimal quality.”

Suboptimal? How about “worthless”?

In response, to the NEJM correction, Merck representatives stated that the company “stands behind the original results” that appeared in the journal.

And to cap off this disaster – beyond all recognition – the Globe reports that Merck has sent an analysis to the FDA that indicates Vioxx heart risks may persist for one full year after a patient discontinues use.

This would all have a comical aspect if not for the deaths and devastated families Vioxx has left in its wake.

A new era

Here’s what’s really sad: If Vioxx were taken off the market today, all of the thousands of current pending lawsuits against Merck might never make it to court.

A new ruling by the FDA went into effect last week, making it much more difficult for consumers to submit liability claims. I’ll be taking a closer look at this in an e-Alert next week. But for now, suffice it to say this is a belated Valentine’s Day gift from the FDA to drug companies. And all I got them was a box of chocolate.

Sources:
“Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial” New England Journal of Medicine, Posted online before publication, 6/26/06, content.nejm.org
“Only a Few Months of Vioxx Could Harm Heart, Journal Says” Diedtra Henderson, The Boston Globe, 6/27/06, boston.com
“New England Journal Charges Merck Deleted Vioxx Study Data” Amanda Gardner, HealthDay, 12/8/05, yahoo.com

Get a free copy of 5 Household Items that Cause Cancer

By texting HSI to 844-539-1128, you are providing your electronic signature expressly consenting to be called and texted (including by prerecorded messages, using an autodialer, and/or automated means) with alerts, stories, reports, and marketing communications from Institute of Health Sciences, LLC. and its authorized representatives at the phone number you provide, including landlines and wireless numbers, even if the phone number is on a corporate, state or national Do Not Call list. You also consent and unconditionally agree to our Privacy Policy and Terms of Use, including the arbitration provision and class action waiver contained therein. Msg&data rates may apply. 15 Msgs/Month. You are not required to agree to this as a condition of making a purchase.

Terms & Conditions

The following Terms and Conditions apply to your use of the website located at hsionline.com (the “website”) and any text messages that you send to or receive from the Institute of Health Sciences, L.L.C. These Terms and Conditions constitute a binding agreement (“Agreement”) between you (“you”) Institute of Health Sciences, L.L.C (“we”, “us”, etc.)  Please read these terms carefully. 

By providing your telephone number to us, texting us a short code listed on the website, or otherwise indicate your agreement to these Terms and Conditions, you are agreeing to the mandatory arbitration provision and class action waiver below. 

ARBITRATION IS MANDATORY AND THE EXCLUSIVE REMEDY FOR ANY AND ALL DISPUTES RELATED TO THIS WEBSITE, THIS AGREEMENT, AND ANY TELEPHONE CALLS, EMAILS, OR TEXT MESSAGES THAT YOU RECEIVE FROM OR ON BEHALF OF US, UNLESS SPECIFIED BELOW OR UNLESS YOU OPT-OUT.

Text Messaging and Telemarketing Terms and Conditions

When you provide your telephone number on this website or send a text message to us with or from a short-code, you agree to receive alerts and communications, and marketing messages including those sent via automated telephone dialing system, text messages, SMS, MMS, and picture messages from Institute of Health Sciences, L.L.C at the phone number you provide on this website or the phone number from which you text the short code, including on landlines and wireless numbers, even if the phone number is on a corporate, state or national Do Not Call list. You also agree to the mandatory arbitration provision and class action waiver below. Your consent is not required to purchase goods or services. Message & data rates may apply.

You may opt-out at any time by texting the word STOP to the telephone number from which you receive the text messages.  Call 1-888-213-0764 to learn more.  By providing your telephone number, you agree to notify us of any changes to your telephone number and update your account us to reflect this change. Your carrier may charge you for text messages and telephone calls that you receive, or may prohibit or restrict certain mobile features, and certain mobile features may be incompatible with your carrier or mobile device. Contact your carrier with questions regarding these issues.

Dispute Resolution by Binding Arbitration and Class Action Waiver

Any dispute relating in any way to telephone calls, emails, or text messages that you receive from or on behalf of Institute of Health Sciences, L.L.C this website, or this Agreement (collectively “Disputes”) shall be submitted to confidential arbitration and shall be governed exclusively by the laws of the State of Maryland, excluding its conflict of law provisions.  For the avoidance of doubt, all claims arising under the Telephone Consumer Protection Act and state telemarketing laws shall be considered “Disputes” that are subject to resolution by binding individual, confidential arbitration.

If a Dispute arises under this Agreement, you agree to first contact us at 1-888-213-0764 or help@hsionline.com. Before formally submitting a Dispute to arbitration, you and we may choose to informally resolve the Dispute.  If any Dispute cannot be resolved informally, you agree that any and all Disputes, including the validity of this arbitration clause and class action waiver, shall be submitted to final and binding arbitration before a single arbitrator of the American Arbitration Association (“AAA”) in a location convenient to you or telephonically. Either you or we may commence the arbitration process by submitting a written demand for arbitration with the AAA, and providing a copy to the other party.  The arbitration will be conducted in accordance with the provisions of the AAA’s Commercial Dispute Resolutions Procedures, Supplementary Procedures for Consumer-Related Disputes, in effect at the time of submission of the demand for arbitration.  Except as may be required by law as determined by the arbitrator, no party or arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written consent of both parties. Institute of Health Sciences, L.L.C will pay all of the filing costs.  Without limiting the foregoing, YOU EXPRESSLY AGREE TO SUBMIT TO ARBITRATION ALL DISPUTES RELATING TO ANY TEXT MESSAGES OR TELEPHONE CALLS YOU RECEIVE FROM OR ON BEHALF OF US OR ANY ENTITY WITH WHOM WE MAY SHARE YOUR TELEPHONE NUMBER.  Further, we both agree that all entities with whom we share your telephone numbers shall be third party beneficiaries of this Agreement to Arbitrate Disputes, and that those entities have the same rights as Institute of Health Sciences, L.L.C to enforce this arbitration provision.

Notwithstanding the foregoing, the following shall not be subject to arbitration and may be adjudicated only in the state and federal courts of Maryland: (i) any dispute, controversy, or claim relating to or contesting the validity of our or one of our family company’s intellectual property rights and proprietary rights, including without limitation, patents, trademarks, service marks, copyrights, or trade secrets; (ii) an action by us for temporary or preliminary injunctive relief, whether prohibitive or mandatory, or other provisional relief; (iii) any legal action by us against a non-consumer; or (iv) interactions with governmental and regulatory authorities.  You expressly agree to refrain from bringing or joining any claims in any representative or class-wide capacity, including but not limited to bringing or joining any claims in any class action or any class-wide arbitration.

The arbitrator’s award shall be binding and may be entered as a judgment in any court of competent jurisdiction. To the fullest extent permitted by applicable law, no arbitration under this Agreement may be joined to an arbitration involving any other party subject to this Agreement, whether through a class action, private attorney general proceeding, class arbitration proceedings or otherwise.

YOU UNDERSTAND THAT YOU WOULD HAVE HAD A RIGHT TO LITIGATE IN A COURT, TO HAVE A JUDGE OR JURY DECIDE YOUR CASE AND TO BE PARTY TO A CLASS OR REPRESENTATIVE ACTION.  HOWEVER, YOU UNDERSTAND AND AGREE TO HAVE ANY CLAIMS DECIDED INDIVIDUALLY AND ONLY THROUGH ARBITRATION.  You shall have thirty (30) days from the earliest of the date that you visit the website, the date you submit information to us through the website, or the date that you send a text message to us, to opt out of this arbitration agreement, by contacting us by email at help@hsionline.com or by mail Health Sciences Institute, PO Box 913, Frederick, MD 21705-0913. If you do not opt out by the earliest of the date that you visit the website, the date you submit information to us through the website, or the date that you send a text message to us, then you are not eligible to opt out of this arbitration agreement.

Electronic Signatures

All information communicated on the website is considered an electronic communication.  When you communicate with us through or on the website, by text message or telephone, or via other forms of electronic media, such as e-mail, you are communicating with us electronically.  You agree that we may communicate electronically with you and that such communications, as well as notices, disclosures, agreements, and other communications that we provide to you electronically, are equivalent to communications in writing and shall have the same force and effect as if they were in writing and signed by the party sending the communication.

You further acknowledge and agree that by clicking on a button labeled “ORDER NOW”, “SUBMIT”, “I ACCEPT”, “I AGREE”, “YES”, by texting a short code to us in response to a request on this website, or by clicking or similar links or buttons, you are submitting a legally binding electronic signature and are entering into a legally binding contract.  You acknowledge that your electronic submissions constitute your agreement and intent to be bound by this Agreement.  Pursuant to any applicable statutes, regulations, rules, ordinances or other laws, including without limitation the United States Electronic Signatures in Global and National Commerce Act, P.L. 106-229 (the “E-Sign Act”) or other similar statutes, YOU HEREBY AGREE TO THE USE OF ELECTRONIC SIGNATURES, CONTRACTS, ORDERS AND OTHER RECORDS AND TO ELECTRONIC DELIVERY OF NOTICES, POLICIES AND RECORDS OF TRANSACTIONS INITIATED OR COMPLETED THROUGH THE WEBSITE.  Furthermore, you hereby waive any rights or requirements under any statutes, regulations, rules, ordinances or other laws in any jurisdiction which require an original signature, delivery or retention of non-electronic records, or to payments or the granting of credits by other than electronic means You may receive a physical paper copy of this contract by contacting us at help@hsionline.com.

Privacy Policy

Please read our Privacy Policy, which is incorporated herein by reference.  In the event of any conflict between these Terms and Conditions and the Privacy Policy, these Terms shall control.

Contact Us

You may contact us by telephone at 1-888-213-0764 or by email at help@hsionline.com.